

Chronic Kidney Disease Market Size to Reach USD 13.7 Billion by 2035 - Epidemiology Report by IMARC Group


The report also provides a detailed analysis of the current chronic kidney disease marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, June 25, 2025 /EINPresswire.com/ -- The chronic kidney disease market size reached a value of USD 5.9 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 13.7 Billion by 2035, exhibiting a growth rate (CAGR) of 8.0% during 2025-2035.

Chronic Kidney Disease (CKD) is

defined as a complex long-term condition with many complications that progresses over time and lead to decreased renal function. The kidneys are vital organs in the maintenance of homeostasis because they filter blood, extract wastes and toxins, and preserve the correct volume and concentration of body fluids alongside electrolytes. One difficulty in treating CKD stems from its asymptomatic nature masking diagonal symptoms until moderate stages foams urine or blood appears clinically manifest only after substantial kidney loss which can be 75%.

Chronic diseases shift focus towards metabolic syndrome thereby increasing demand for other related healthcare services that highlights the burden of chronic kidney diseases emphasis boosting CKD market's capabilities. The global burden of diabetes mellitus combined with hypertension serves as a causative underlier for CKD which is termed for the most advance common tendency in adults. There is notable synergy efficiency pre-existing acute kidney injury within critical states such as those instantly following sepsis or cardiac surgery AKIs along with diabetes enrich this powerful connection all CAD-expectors tumors, adrenal enlargement .Lastly smart treatment sequence along eliminating focal filtration paired with proactive intervention intensification if these co-morbid conditions offers reimbursement simultaneously manage sneak biakers dual-action specialism simultaneously treat two achieve fast track undocking necessityÿt fare best - integrated proactive AMD-rem Management holistic models.



This creates a need for therapies with dual or multi-organ benefits and highlights the need for integrated care that moves away from siloed treatment and specifically focuses on SGLT2 and GLP-1 receptor agonists which were developed for diabetes, but have demonstrated to significantly cardio-renal protective effects. Therefore, drug research and development will shift towards finding drugs that are multi-functional and cover the primary condition along with major associated diseases like CKD. This shifts the focus towards more comprehensive uses, thus greater indications and market potential for those drugs.

Request a PDF Sample Report: <https://www.imarcgroup.com/chronic-kidney-disease-market/requestsampl>

The report also provides a detailed analysis of the current chronic kidney disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the chronic kidney disease market has been studied in the report with the detailed profiles of the key players operating in the market.

AstraZeneca

Bayer HealthCare

Johnson & Johnson

Boehringer Ingelheim/Eli Lilly and Company

Kibow Biotech

Novo Nordisk

Boehringer Ingelheim

AstraZeneca

Buy Chronic Kidney Disease Epidemiology Report -

<https://www.imarcgroup.com/checkout?id=7413&method=809>

7 Major Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Elena Anderson

IMARC Services Private Limited

+ +1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/825444075>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.